Patients requiring missing data imputation* for change from baseline in total PsA-modified vdH-S score at wk 24; randomised patients in PSUMMIT-1 and PSUMMIT-2
| Ustekinumab | |||
|---|---|---|---|
| Placebo (%) | 45 mg (%) | 90 mg (%) | |
| Patients in PSUMMIT-1 + PSUMMIT-2, n | 310 | 308 | 309 |
| Requiring median imputation | 32 (10.3) | 12 (3.9) | 15 (4.9) |
| Requiring linear extrapolation | 7 (2.3) | 7 (2.3) | 10 (3.2) |
| Patients in PSUMMIT-1, n | 206 | 205 | 204 |
| Requiring median imputation | 12 (5.8) | 6 (2.9) | 5 (2.5) |
| Requiring linear extrapolation | 3 (1.5) | 5 (2.4) | 5 (2.5) |
| Patients in PSUMMIT-2, n | 104 | 103 | 105 |
| Requiring median imputation | 20 (19.2) | 6 (5.8) | 10 (9.5) |
| Requiring linear extrapolation | 4 (3.8) | 2 (1.9) | 5 (4.8) |
| Anti-TNF naive patients, n | 42 | 43 | 47 |
| Requiring median imputation | 5 (11.9) | 2 (4.7) | 3 (6.4) |
| Requiring linear extrapolation | 1 (2.4) | 0 | 2 (4.3) |
| Anti-TNF-experienced patients, n | 62 | 60 | 58 |
| Requiring median imputation | 15 (24.2) | 4 (6.7) | 7 (12.1) |
| Requiring linear extrapolation | 3 (4.8) | 2 (3.3) | 3 (5.2) |
*Missing X-ray data were imputed via linear extrapolation if X-ray data were available at two time points during the period from wk 0 to wk 24, or from wk 24 to wk 52 or, if radiographic data were insufficient for linear extrapolation, via assignment of the median of the change in the total scores based on all patients within the same MTX stratification at the missing visit.
anti-TNF, anti-tumour necrosis factor α; MTX, methotrexate; PsA, psoriatic arthritis; vdH-S, van der Heijde-Sharp; wk, week.